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ABSTRACT
This is an update of a randomized study on antithymocyte globulin (ATG; Thymoglobulin) before transplan-
tation in patients undergoing unmanipulated marrow transplantation from unrelated donors. The median
follow-up for surviving patients is 5.7 years. At last follow-up, chronic graft-versus-host disease (GVHD) was
scored in 60% of non-ATG and in 37% of ATG patients (P  .05), and extensive chronic GVHD was present
in 41% and 15%, respectively (P .01). Chronic lung dysfunction was diagnosed in 51% versus 19% of patients
(P  .005). Forced vital capacity decreased significantly with time in non-ATG patients (P  .005), but not in
patients who received ATG (P .30). The proportion of patients with Karnofsky scores of>90% at 4 years was
57% versus 89% in non-ATG versus ATG patients (P  .03). The actuarial 6-year survival for all patients
randomized was 31% versus 44% (non-ATG versus ATG; P  .80). The cumulative incidence of transplant-
related mortality was 51% versus 41% (P .70) and of relapse was 32% versus 40% (P .90). For patients who
survived 1 year, transplant-related mortality was 25% versus 3% (P  .03), and actuarial survival was 58%
versus 85% (P  .09). In conclusion, the addition of ATG to cyclosporine/methotrexate provides significant
protection against extensive chronic GVHD and chronic lung dysfunction, reduces late transplant mortality,
and improves quality of life in patients undergoing unrelated donor transplantation.
© 2006 American Society for Blood and Marrow Transplantation
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tNTRODUCTION
Chronic graft-versus-host disease (GVHD) re-
ains a major complication of allogeneic bone mar-
ow transplantation (BMT) and has a signiﬁcant effect
n quality of life and late mortality [1,2]. Because of
he increased risk of chronic GVHD in patients who
eceive alternative donor grafts [3], several centers G
60ave been using antithymocyte globulin (ATG) dur-
ng the conditioning regimen or early after transplan-
ation in addition to the conventional cyclosporine/
ethotrexate prophylaxis [4-9]. These studies have
hown that patients who receive ATG have a reduced
ncidence and severity of acute and chronic GVHD:
he reduction is in the order of 20% for both acute
VHD grade II to IV and chronic GVHD [10].
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Randomized Trial of ATG in Unrelated Transplantations
Bhese data have been conﬁrmed by 3 randomized
tudies [11-13]. It is less clear whether survival is
ffected: in one trial, we were able to conﬁrm a pro-
ective effect of ATG on acute and chronic GVHD,
ut we could show no effect on transplant-related
ortality (TRM) and survival at 3 years [13]. The last
atient in this study [13] was entered on July 12, 2000,
o the minimum follow-up for surviving patients is
ow 5 years, and the median follow-up is 5.3 years.
he aim of this article is to assess the long-term risk of
hronic GVHD, chronic lung dysfunction (CLD),
uality of life, survival, and TRM in patients random-
zed to receive or not receive ATG.
ATIENTS AND METHODS
tudy Design
The original study has been published [13]:
rieﬂy, 109 patients undergoing unrelated donor
ransplantation were randomized in 4 centers from the
talian Group for Marrow Transplantation to receive
r not receive ATG (Thymoglobulin; Genzyme,
ambridge, MA; 7.5-15 mg/kg) in the conditioning
egimen. All patients were prepared with conventional
yclophosphamide and total body irradiation, fol-
owed by cyclosporine/methotrexate as GVHD pro-
hylaxis [13].
able 1. Clinical Data of Patients Receiving or Not Receiving ATG
efore Transplantation Who Were Alive on Day 100
No. Patients
No ATG
(n  37)
ATG
(n  38) P Value
o. of patients in trial 1 20 21
o. of patients in trial 2 17 17 .60
edian age, y (range) 26 (13-51) 27 (16-44) .80
with early disease 60% 47% .20
iagnosis
Acute leukemia 11 11
Chronic myeloid leukemia 25 27
Myelodysplasia 1 0 .90
ollow-up (d)
Median 2078 2065
Range 108-3159 108-3196
hronic GVHD
(limited  extensive) 60% 37% .05
hronic GVHD (extensive) 41% 15% .01
hronic lung dysfunction 51% 19% .005
with Karnofsky >90%
at 4 y 57% 89% .03
ransplant-related deaths 11 (30%) 6 (16%) .10
Chronic GVHD 9 4
Respiratory failure 2 0
Other 0 2
elapse-related deaths 7 (19%) 7 (18%) .50
o. patients alive 19 (51%) 25 (66%) .10
TG indicates antithymocyte globulin; GVHD, graft-versus-host
fdisease.
B&MTatients
Seventy-ﬁve patients survived 100 days after BMT
ith a median follow-up of 2000 days. Patients ran-
omized to the non-ATG (n  37) or ATG (n  38)
roup were matched for age, disease, and disease
hase (Table 1). Each patient was updated for survival,
hronic GVHD, CLD, relapse of the original disease,
nd quality of life assessed by Karnofsky score.
hronic GVHD and Lung Function
Chronic GVHD was diagnosed according to es-
ablished clinical criteria as absent, limited, or exten-
ive [14]. Data on respiratory complications were
vailable in 67 patients: 35 in the non-ATG and 32 in
he ATG group. CLD [15] was diagnosed when pa-
ients complained of breathlessness at rest in the ab-
ence of infectious causes: computed tomography of
he thorax and spirometric studies—namely, forced
xpiratory volume in 1 second (FEV1), forced vital
apacity (FVC), and carbon monoxide diffusing ca-
acity—were used to conﬁrm the diagnosis. Typi-
ally patients presented with a longitudinal reduc-
ion in both FEV1 and FVC (with the FEV1/FVC
atio within normal limits or increased), thus sug-
esting a restrictive defect [16], combined with a
ecrease in carbon monoxide diffusing capacity.
arnofsky scores, taken at different times after
ransplantation, were available.
tatistical Analyses
The NCSS package (J. Hinze, Kaysville, UT) was
sed for 2 tables, actuarial survival, cumulative inci-
ence rates, Student t tests, Mann-Whitney tests, and
-dimensional plots. The data are presented as non-
TG patients (controls) versus ATG patients, thus
erging ATG 7.5 and 15 mg/kg: this is due to the
mall number of patients, but differences, when
resent, are described.
ESULTS
hronic GVHD
At last follow-up, chronic GVHD was scored in
0% versus 37%, respectively, for non-ATG and
TG patients (P  .05). Extensive chronic GVHD
as present in 41% versus 15% (P  .01; Figure 1).
hronic Lung Dysfunction
The cumulative incidence of CLD was 51% for
on-ATG versus 19% for ATG patients (P  .005;
igure 2). In the non-ATG group, there was a signif-
cant decrease of FEV1 beyond 2 years (average 
f 23%; P  .02), and the same was true for FVC
average  of 20%; P  .005). This was not the case
or patients who received ATG (FEV1, 3%, P 
561
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520; FVC,3%, P .30). The median FEV1/FVC
atio was 1.02 and 1.04 for non-ATG and ATG pa-
ients, respectively. Bidimensional plots of FVC in the
groups, expressed as percentages of predicted values,
re outlined in Figure 3. ATG patients had stable
VC with time, whereas non-ATG patients exhibited
rogressive worsening of FVC, with average FVC of
ust over 50% 2500 days after transplantation.
uality of Life
The proportion of patients with a Karnofsky score of
90% in the non-ATG versus ATG patients was 28%
ersus 44% at 1 year (P  .20), 62% versus 63% at 2
ears (P  .90), 56% versus 95% at 4 years (P  .005),
nd 57% versus 89% beyond 4 years (P .03; Table 1).
igure 1. The incidence of chronic graft-versus-host disease
GVHD) at last follow-up is lower in patients who receive antithy-
ocyte globulin (ATG) in the conditioning regimen: this is more
igniﬁcant for extensive chronic GVHD.
igure 2. There was a signiﬁcantly higher cumulative incidence
CI) of chronic lung dysfunction in patients randomized to theron-ATG arm.
62urvival and TRM
The actuarial 6-year survival for all patients ran-
omized is 31% versus 44% in the non-ATG and
TG groups (P  .80; Figure 4A), and in patients
urviving 1 year, it is 58% versus 85%, respectively
P  .09), with more late events in the non-ATG
roup (Figure 4B). Similarly, the overall cumulative
ncidence of TRM is 51% (non-ATG) versus 41%
P  .70; Figure 5A). In patients surviving 1 year, it is
5% versus 3% (P  .03; Figure 5B).
auses of Death
Relapse-related deaths were 19% in the non-ATG
nd 18% in the ATG group (P .50). Other causes of
eath are outlined in Table 1.
ISCUSSION
We have shown in this study that ATG given
efore transplantation (1) provides signiﬁcant protec-
ion against chronic GVHD in patients undergoing
nrelated donor BMT with cyclosporine/methotrex-
te prophylaxis, (2) reduces the risk of CLD, (3) im-
roves quality of life, and (4) reduces late TRM.
The ﬁrst ﬁnding relates to the effect of ATG on
hronic GVHD, already described in the original
tudy [13] and in keeping with other retrospective
tudies [4-9]. These studies, involving almost 1000
atients, have all shown a reduction in the order of
0% to 30% of chronic GVHD in patients who
igure 3. Bidimensional plots of forced vital capacity (FVC) ex-
ressed as percentage of predicted in patients who received or did
ot receive ATG and days after BMT. The linear ﬁt for trend and
5% conﬁdence limits (CL) are shown. FVC (percentage of pre-
icted) and days from BMT are displayed on the y- and x-axis,
espectively. Vertical bars represent determinations with 95% CL.
TG patients (58 determinations in 22 patients) show a relatively
table FVC (percentage of predicted), whereas the non-ATG group
38 determinations in 16 patients) shows a continuous decline in this
arameter with time.eceive ATG [10], although retrospective studies
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Ban be biased by selection of patients for one treat-
ent or the other. We believe that the strengths of
his study are the prospective randomized nature of
he trial and the long median follow-up of 2000
ays. The small number of patients is a drawback,
specially when they are broken down according to
he dose of ATG received (15 or 7.5 mg/kg): never-
heless, the results showed a signiﬁcant difference
hen ATG patients were compared with controls. We
re showing in this article chronic GVHD as assessed
t last follow-up, because this takes into account treat-
ent and responses. The protective effect of ATG on
hronic GVHD included the limited form, but more
o the extensive form, of the disease: this is important
ecause it is the persistence of the latter that exposes
atients to a high risk of severe complications [2],
ncluding chronic lung dysfunction.
CLD can be restrictive, obstructive, or mixed [15]:
he restrictive form seems to be more sensitive to
mmunosuppressive therapy, whereas the obstructive
orm is not [15]. In this study, the FEV1/FVC ratio of
igure 4. A, Actuarial survival from transplantation of patients
andomized to the ATG arm (n  56) or non-ATG arm (n  53).
, Actuarial survival of patients randomized to the ATG arm (n 
9) or non-ATG arm (n  28) who were alive 1 year after trans-
lantation.ur patients was close to 1 or more, thus suggesting w
B&MThat the restrictive defect predominated. Despite this,
e have seen little response to immunosuppressive
herapy: some of these patients have had progressive
ung dysfunction necessitating chronic oxygen supple-
entation and eventual admission to an intensive care
nit. CLD has been associated with chronic GVHD
17]. Actually, CLD could be considered a form of
ung GVHD. In this study, the cumulative incidence
f CLD was signiﬁcantly higher in non-ATG patients
ompared with ATG patients. Bidimensional plots of
VC, expressed as percentages of expected values,
ndicate 2 separate patterns of evolution: the ATG
atients show relatively stable average FVC, whereas
he non-ATG group shows a continuous decline of
VC with time that is suggestive of a progressive
estrictive defect. Two patients died recently of respi-
atory insufﬁciency in intensive care units, and 2 ad-
itional patients have severe restrictive defects that
ecessitate oxygen supplementation: all of these are in
he non-ATG group. As a consequence, ATG pa-
ients, who survive their transplantation with less
igure 5. A, Cumulative incidence (CI) of transplant-related mor-
ality (TRM) of patients randomized to the ATG arm (n  56) or
on-ATG arm (n  53). B, Actuarial 9-year survival of patients
andomized to the ATG arm (n  29) or non-ATG arm (n  28)
ho were alive 1 year after transplantation.
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5hronic GVHD and fewer respiratory problems, have
better quality of life, as indicated by Karnowsky
cores 90%, and this has become more evident as
ime goes by.
If the form of chronic GVHD prevented by ATG
s clinically relevant, then one should see an effect on
RM: indeed, TRM was comparable at the time of
he original publication [9] and also in this study up to
year after transplantation. With longer follow-up,
RM starts to diverge 1 to 2 years after transplanta-
ion, and 2000 days after transplantation ATG pa-
ients have a lower rate of TRM per year as compared
ith non-ATG patients. Relapse-related deaths were
omparable, as was long-term survival, with a trend in
avor of ATG patients, although the numbers are small.
Are these data sufﬁcient to suggest that ATG
hould be used in all patients undergoing an unrelated
onor transplantation? Many centers would disagree,
nd this is primarily based on the results of ex vivo
-cell depletion: that is, removal of T cells from the
raft before it is infused into the patient. A large
nternational Bone Marrow Transplantation Registry
tudy has shown that there is no overall advantage
or ex vivo T-cell depletion over unmanipulated
rafts [18], despite the reduction of GVHD, the
rincipal cause of failure in allogeneic transplanta-
ion. Second, ATG is not without side effects, and
rawbacks include an increased risk of early bacte-
ial infections [10], Epstein-Barr virus reactivation,
nd Epstein-Barr virus–associated lymphoprolifera-
ive disease [19]; there also may be an increased risk
f relapse associated with a reduced graft-versus-
eukemia effect [20]. Third, there have been very few
rospective randomized studies, usually with short fol-
ow-up, and there has been little time to observe late
vents. In this study, despite small numbers of patients,
e have shown that ATG can prevent chronic GVHD
nd CLD, but more importantly, we are suggesting that
t may take 4 to 5 years before chronic GVHD produces
ts negative effects on quality of life and mortality.
If this is true, this study would also suggest that a
-drug combination, such as cyclosporine/methotrex-
te, does not provide sufﬁcient protection in the un-
elated donor setting against chronic GVHD and late
omplications. This may be relevant at a time when
ore unrelated transplantations are being performed
nd when peripheral blood is increasingly used as a
tem cell source. Also, prospective trials comparing
TG patients versus controls are difﬁcult to set up,
iven the very long time it takes for planning and
ollow-up to capture late events. We are currently
orking on protocols involving different ATG timing
nd schedules [18], and perhaps this triple combina-
ion—ATG, cyclosporine, and methotrexate—may be
ompared with other 3-drug combinations.
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